ERBB2 and gastric cancer: In the Trastuzumab for Gastric Cancer (ToGA) trial, the overall HER2 positive rate was 23.2% for biopsy specimens and 19.7% for surgical specimens, which makes HER2 an available molecular phenotype recommended for preoperative evaluation (Van Cutsem et al., 2015).